ClinicalTrials.gg
RecruitingNCT05046496TRASOSUpdated Sep 29, 2023

Transplant Renal Artery Stenosis: Observation Versus Stenting

An interventional study of Intra-arterial digital subtraction angiography in Transplant Renal Artery Stenosis, sponsored by Imperial College Healthcare NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-29.

Sponsored by Imperial College Healthcare NHS Trust · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Aug 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Transplant renal artery stenosis (TRAS) is abnormal narrowing of the main blood vessel to the kidney transplant and has historically been considered a surgical complication. In heart transplantation, it has long been recognised that rejection can cause narrowing of the heart's blood vessels, and that this complication is the leading cause of heart transplant failure. It is reasonable to assume that this process may also occur in kidney transplantation, which could contribute to premature transplant failure. However, in kidney transplantation it is also likely that other factors, such as surgical factors, traditional cardiovascular risk factors and immunological factors, contribute to the development of TRAS. Given that the disease processes that cause TRAS are not fully understood, at present there is no consensus among kidney doctors on the best means of treating patients diagnosed with TRAS. The aim of the proposed study is to investigate the involvement of these different processes in the development of TRAS, and investigate the optimal way to diagnose and manage TRAS.

At present, there is no standard recommendation for how to treat patients with TRAS. This is partly due to the fact that patients with TRAS may have a broad array of symptoms: Some may have no symptoms, other may have problems with high blood pressure or fluid accumulation, and others may have severe transplant dysfunction. In most transplant centres, patient TRAS and severe symptoms will undergo IADSA and a stent will be placed to open the narrowing. However, it is not clear how best to manage patients with TRAS who have mild to moderate symptoms. We propose to recruit 36 such patients to a clinical study and split them into two groups: One group to undergo IADSA with possible stent placement, and one group to be closely observed. We will then compare transplant function, and other outcomes, after one year between the two groups.

Read the detailed description

Transplant renal artery stenosis (TRAS) is abnormal narrowing of the main blood vessel to the kidney transplant and has historically been considered a surgical complication. In heart transplantation, it has long been recognised that rejection can cause narrowing of the heart's blood vessels, and that this complication is the leading cause of heart transplant failure. It is reasonable to assume that this process may also occur in kidney transplantation, which could contribute to premature transplant failure. However, in kidney transplantation it is also likely that other factors, such as surgical factors, traditional cardiovascular risk factors and immunological factors, contribute to the development of TRAS. Given that the disease processes that cause TRAS are not fully understood, at present there is no consensus among kidney doctors on the best means of treating patients diagnosed with TRAS. The aim of the proposed study is to investigate the involvement of these different processes in the development of TRAS, and investigate the optimal way to diagnose and manage TRAS.

At present, there is no standard recommendation for how to treat patients with TRAS. This is partly due to the fact that patients with TRAS may have a broad array of symptoms: Some may have no symptoms, other may have problems with high blood pressure or fluid accumulation, and others may have severe transplant dysfunction. In most transplant centres, patient TRAS and severe symptoms will undergo IADSA and a stent will be placed to open the narrowing. However, it is not clear how best to manage patients with TRAS who have mild to moderate symptoms. We propose to recruit 36 such patients to a clinical study and split them into two groups: One group to undergo IADSA with possible stent placement, and one group to be closely observed. We will then compare transplant function, and other outcomes, after one year between the two groups.

02

Conditions studied

  • Transplant Renal Artery Stenosis

Keywords

  • Kidney transplant
  • Transplant renal artery stenosis
03

In context

Renal Artery Obstruction

59 studies on the registry are indexed under Renal Artery Obstruction; 10 are open to participants now.

This study's planned enrollment of 36 is below the median of 100 across 42 interventional studies indexed under Renal Artery Obstruction.

Browse Renal Artery Obstruction studies →

Lead sponsor

Imperial College Healthcare NHS Trust is the lead sponsor of 80 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Renal transplant recipient with a diagnosis of TRAS by radiological imaging, and an MDT decision to proceed with diagnostic IADSA.
  1. Aged 18 years and over 3. Able to give

Exclusion criteria

Exclusion Criteria:

    1. Estimated \<10mls/min/1.73m2 or dialysis dependence 2. to angiography (e.g. allergy to radiological contrast) 3. Patients with clinical features of severe TRAS (eg. resistant hypertension, pulmonary oedema and/or rapidly deteriorating function).
  1. Any condition or co-morbidity which in the investigator's opinion would make the patient ineligible for the trial or unlikely to adhere to trial procedures.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • No intervention
    Observational arm

    Patients recruited to this arm will undergo no intervention.

  • Active comparator
    Interventional arm

    Patients recruited to this arm will undergo intra-arterial digital subtraction angiography, with or without intra-arterial stent placement

    Diagnostic Test: Intra-arterial digital subtraction angiography

Interventions

  • Diagnostic testIntra-arterial digital subtraction angiography

    Invasive intra-arterial angiography, with intra-arterial stent placement if a stenosis is confirmed

06

What researchers measure

Primary outcomes

  1. Change in eGFR between both arms

    measure of kidney transplant function

    Time frame: 1 year

Secondary outcomes

  1. Change in estimated glomerular filtration rate (eGFR)

    measure of kidney transplant function

    Time frame: at baseline, then 1, 3, 6 and 12-months following diagnosis

  2. Change in mean arterial blood pressure (BP), systolic BP and diastolic BP

    Measure of cardiovascular health

    Time frame: at baseline, then 1, 3, 6 and 12-months following diagnosis

  3. Average number of anti-hypertensive medications

    measure of cardiovascular health

    Time frame: at baseline, then 1, 3, 6 and 12-months following diagnosis

  4. Urinary protein : creatinine ratio (UPCR) measurement

    measure of proteinuria

    Time frame: at baseline, then 1, 3, 6 and 12-months following diagnosis

  5. Donor-specific antibody (DSA) free survival

    measure of time free from presence of donor-specific antibody in participant's serum

    Time frame: 1 year

  6. Rejection free survival

    measure of time free from histologically proven kidney transplant rejection

    Time frame: 1 year

  7. Renal allograft failure

    Measure of time free from kidney transplant failure

    Time frame: 1 year

  8. Patient survival

    measure of patient survival

    Time frame: 1 year

  9. Requirement for intervention (primary angiogram in observational group, secondary angiogram in interventional group)

    Quantification of patients that require intervention

    Time frame: 1 year

Other outcomes

  1. Adverse event reporting

    reporting of any adverse events that afflict study participants

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2021 (actual). Primary completion is estimated for Aug 2024, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2021
First posted
Sep 16, 2021
StartActual
Aug 28, 2021
Primary completionEst.
Aug 2024
CompletionEst.
Aug 2025
Last update
Sep 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05046496
Lead sponsor
Imperial College Healthcare NHS Trust
Responsible party
Sponsor
First posted
Sep 16, 2021
Start date
Aug 28, 2021
Primary completion
Aug 2024 (estimated)
Completion
Aug 2025 (estimated)
Last update
Sep 29, 2023

Study contacts

Paul Martin
Contact
paul.martin9@nhs.net
02033136641
Michelle Willicombe
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion